ABE JEROME BLOG

DUBLIN--(BUSINESS WIRE)--The "Disease Analysis: Type 1 Diabetes" report has been added to ResearchAndMarkets.com's offering.

The research estimates that in 2018, there were approximately 46.6 million prevalent cases of type 1 diabetes in adults aged 20 years and over worldwide, and forecasts that number to increase to 51.8 million prevalent cases by 2027.

In children and adolescents aged below 20 years, there were approximately 1.08 million prevalent cases of type 1 diabetes worldwide in 2018, which are expected to increase to 1.12 million prevalent cases by 2027.

The overall likelihood of approval of a Phase I type 1 diabetes asset is 16.3%, and the average probability a drug advances from Phase III is 73.9%. Type 1 diabetes drugs, on average, take 8.5 years from Phase I to approval, which is the same as the average duration to approval in the overall endocrine space.

It is expected that patients will continue to switch from Novo Nordisk's Levemir to its successor product Tresiba due to the company's promotion of Tresiba's longer duration of blood sugar control compared to Levemir.

Likewise, Sanofi is pursuing a comparable commercial strategy to Novo Nordisk by promoting its next-generation insulin glargine product Toujeo over Lantus, as Lantus continues to lose patient share to the more affordable biosimilar Basaglar. However, key opinion leaders interviewed by the research anaylysts suggest that physicians are unconvinced that Toujeo possesses tangible benefits over biosimilar insulin glargine to justify its higher price.

Payers are severely restricting the use of specific insulin brands in the US. As the list price of insulins continues to increase, cost is becoming a strong determining factor for the choice of insulin treatment. Interviewed endocrinologists emphasized the impact of pricing on prescribing trends, as price fluctuations in the US lead to regular switching among patients.

Tresiba is forecasted to see the greatest uptake of all the long-acting insulin therapies in type 1 diabetes. Its long-acting duration of 42+ hours and its flexible dosing window (it can be administered at different times each day) offer improved convenience for patients, along with strong glycated hemoglobin (HbA1c) reductions. In addition, favorable pricing compared to Lantus and Toujeo within the US market is expected to drive growth of Novo Nordisk's market share.

Key Topics Covered:

1. OVERVIEW

2. DISEASE BACKGROUND

Disease definition

Patient segmentation

Disease diagnosis

3. TREATMENT

Daily insulin replacement therapy is required to prevent hyperglycemia

4. EPIDEMIOLOGY

Prevalence in adults (20-85+ years)

Prevalence in children and adolescents (0-19 years)

5. MARKETED DRUGS

6. PIPELINE DRUGS

7. KEY REGULATORY EVENTS

Empagliflozin Likely Needs Another Trial After Rebuke By US FDA Panel

EMA Accepts First Diabetes Drug Onto PRIME

AstraZeneca's Farxiga Fails To Get FDA OK As Insulin Supplement In Type 1 Diabetes

Sanofi Files First Biosimilar Insulin Aspart In Challenge To NovoRapid

AZ's Forxiga Gets Type 1 Diabetes EU Okay As Sanofi Suffers US Setback

8. PROBABILITY OF SUCCESS

9. LICENSING AND ASSET ACQUISITION DEALS

With $260m Settlement From Sanofi, Lexicon Looks For New Zynquista Partner

10. CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

11. DRUG ASSESSMENT MODEL

Long-acting insulins

Rapid-acting insulins

Non-insulin treatments

12. MARKET DYNAMICS

Current dynamics

Market opportunity

Threat of substitution

Payer pressure / buyer power

13. FUTURE TRENDS

Questionable clinical benefit and pricing pressure from biosimilars will slow uptake of next-generation products

Pricing pressure in the US diabetes market will shift prescribing trends towards affordable insulins

Teplizumab uptake will be dependent on overcoming pricing and reimbursement issues, along with the introduction of screening programs to identify at-risk patients

SGLT-2 inhibitors are expected to have slow uptake in the EU and Japan due to narrow target populations, DKA risk, and minor glycemic benefits

14. CONSENSUS FORECASTS

15. RECENT EVENTS AND ANALYST OPINION

Zynquista for Type 1 Diabetes (December 02, 2019)

Jardiance for Type 1 Diabetes (November 13, 2019)

Jardiance for Type 1 Diabetes (November 11, 2019)

Toujeo for Type 1 Diabetes (October 31, 2019)

Farxiga for Type 1 Diabetes (July 15, 2019)

SAR341402 for Type 1 Diabetes (June 9, 2019)

LY900014 for Type 1 Diabetes (June 9, 2019)

Teplizumab for Type 1 Diabetes (June 9, 2019)

Multiple Drugs for Type 1 Diabetes (June 8, 2019)

HDV-L for Type 1 Diabetes (June 8, 2019)

TTP399 for Type 1 Diabetes (June 6, 2019)

NN9828 for Type 1 Diabetes (May 31, 2019)

Zynquista for Type 1 Diabetes (March 22, 2019)

CLBS03 for Type 1 Diabetes (February 13, 2019)

16. KEY UPCOMING EVENTS

17. KEY OPINION LEADER INSIGHTS

18. UNMET NEEDS

Better options for glucose administration

Innovative therapies with new mechanisms of action

Prevention of type 1 diabetes

Faster-acting short-acting analogs

19. BIBLIOGRAPHY

20. APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/9on4xf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.